{"entity":{"id":"nct06634849","kind":"trial","name":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).","aka":[],"tldr":"A phase 1/2 trial of PTT-4256 in advanced solid tumours, run by Pathios Therapeutics Pty Ltd, now recruiting.","summary":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). is a phase 1/2 interventional study registered as NCT06634849 by Pathios Therapeutics Pty Ltd, with 30 participants planned, started 2024-11-04 and due to reach its primary completion in 2027-04-30. Interventions recorded: PTT-4256.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06634849","url":"https://clinicaltrials.gov/study/NCT06634849"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06634849","phase":"1/2","setting":"A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256.","sponsor":"Pathios Therapeutics Pty Ltd","enrolled":30,"outcomes":[]},"route":"/trials/nct06634849/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}